Specialist scientific platforms selling to a narrow research audience.
Metabolomics and other omics platforms sell highly specialised analytical capability to a narrow research and pharmaceutical audience, where credibility depends on genuine scientific depth, not marketing polish.
This audience is small, technically expert, and reads content skeptically. A researcher or pharma partner evaluating an omics platform checks methodology, data quality and publication record closely, and generic scientific marketing language is immediately discounted.
Content built with genuine scientific depth for a peer-level reader, publication and methodology evidence presented credibly, and a platform that serves a narrow, specific audience precisely rather than broadly.
Every technical statement on the site is built from material your scientific team supplies and verifies first — we structure and present it, we don’t generate the science.
The scope our work with metabolomics and omics companies has operated within.
The build priorities for a peer-level scientific audience differ from a general commercial one. Here is what metabolomics and omics companies most often need.
How this work is approached specifically for Metabolomics and Omics.
What comes up when building for a specialist scientific platform.
Every technical statement is built from material your scientific team supplies and verifies, not written independently, since methodology and analytical claims in this field carry weight only when a peer-level reader can trace them back to your own validated data. We structure and present that material for that reader — organising methods, datasets and citations clearly — rather than originating scientific content that has not come from your team first.
Omics platforms serve a narrower, methodology-focused research audience than general biotech content typically addresses, since a researcher evaluating a metabolomics or proteomics platform is checking analytical method, reproducibility and data standards rather than a therapeutic pipeline story. Biotech covers the broader clinical-stage company audience, while this content has to speak directly to the technical evaluation criteria a platform scientist applies before adoption.
Complex analytical processes are illustrated through accuracy-checked visuals built in direct review with your scientific team, since a diagram of a metabolomic pathway or workflow that oversimplifies a step will lose credibility with exactly the peer-level audience it needs to convince. Scientific illustration for this sector prioritises technical correctness over visual polish, because a reviewer who spots an inaccurate step tends to distrust the surrounding content too.
Validation, reproducibility and standards-compliance data — including reporting aligned with frameworks like the Metabolomics Standards Initiative — is structured as clearly sourced, checkable technical content rather than as marketing claims, since this audience is trained to look past unreferenced performance statements. Every technical claim links back to the study or dataset your scientific team supplies, because a platform scientist will look for that evidence before considering adoption.
Related sectors worth reviewing alongside metabolomics and omics.
A scientific platform that needs to read as credible to a peer-level audience. Tell us your platform and we will tell you how we would approach it for a metabolomics and omics company.